Format

Send to

Choose Destination
Trends Biotechnol. 2019 Jul;37(7):680-683. doi: 10.1016/j.tibtech.2019.02.006. Epub 2019 Mar 16.

Inter Partes Review: Patent Killer No More?

Author information

1
Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Miaoli County, Taiwan; School of Law, National Chiao Tung University, Hsinchu, Taiwan; School of Dentistry, China Medical University, Taichung, Taiwan. Electronic address: fcchen@nhri.org.tw.
2
School of Law, National Chiao Tung University, Hsinchu, Taiwan; School of Law, Duke University, Durham, NC, USA.

Abstract

Inter Partes review (IPR) can efficiently invalidate drug patents and potentially convey strategic advantages to follow-on drug makers. However, recent changes in the IPR system foretell a tectonic shift in the landscape. Here we summarize these major changes and discuss the implications for the biopharmaceutical community.

KEYWORDS:

Biologics Price Competition and Innovation Act; Hatch-Waxman Act; Inter partes review; patent infringement

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center